New EUR420m Fund for Life Sciences in Luxembourg
New York - US-American investment firm OrbiMed announced the closing of a new fund for life science companies in the health sector. The fund acquires healthcare royalty streams and provides structured debt capital to healthcare companies. "Royalty Opportunities sarl" is domiciled in Luxembourg and will invest in Europe and worldwide. The fund managers have significant cash at their hands: the investors having forked out some €420m.
"Life sciences companies are typically dependent on equity markets to raise new capital," observed Tadd Wessel, a Managing Director on the Royalty Opportunities team. "With this fund, OrbiMed can offer a minimally dilutive capital alternative to fund product launches, M&A opportunities, new product research, and general corporate purposes."
OrbiMed Advisors LLC is a investment firm dedicated exclusively to the healthcare sector, with more than $5 billion in assets under management. OrbiMed invests across the entire spectrum of healthcare companies on a worldwide basis.